GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis
NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD
GMAB gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB is growing strongly while it also seems undervalued. This is an interesting combination This makes GMAB very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
GMAB had positive earnings in the past year.
In the past year GMAB had a positive cash flow from operations.
In the past 5 years GMAB has always been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
GMAB has a better Return On Assets (17.12%) than 96.97% of its industry peers.
GMAB has a better Return On Equity (21.38%) than 96.61% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.92%, GMAB belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 15.87%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROIC | 13.92% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
1.3 Margins
Looking at the Profit Margin, with a value of 36.44%, GMAB belongs to the top of the industry, outperforming 97.86% of the companies in the same industry.
GMAB's Profit Margin has declined in the last couple of years.
GMAB's Operating Margin of 32.18% is amongst the best of the industry. GMAB outperforms 98.04% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
GMAB's Gross Margin of 95.42% is amongst the best of the industry. GMAB outperforms 94.47% of its industry peers.
In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
GMAB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
GMAB has an Altman-Z score of 7.81. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
GMAB's Altman-Z score of 7.81 is amongst the best of the industry. GMAB outperforms 83.96% of its industry peers.
GMAB has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.14, GMAB belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
GMAB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, GMAB is in line with its industry, outperforming 40.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 7.81 |
ROIC/WACC1.97
WACC7.05%
2.3 Liquidity
A Current Ratio of 5.25 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Current ratio (5.25) which is in line with its industry peers.
GMAB has a Quick Ratio of 5.24. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a Quick ratio (5.24) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 |
3. Growth
3.1 Past
GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.67%, which is quite impressive.
GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 29.12% yearly.
GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.67%.
Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 32.03% on average per year.
EPS 1Y (TTM)24.67%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%-89.84%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%14.19%
3.2 Future
Based on estimates for the next years, GMAB will show a small growth in Earnings Per Share. The EPS will grow by 7.42% on average per year.
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 11.53% on average per year.
EPS Next Y-12.51%
EPS Next 2Y2.37%
EPS Next 3Y8.76%
EPS Next 5Y7.42%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.53%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 12.82, which indicates a correct valuation of GMAB.
Based on the Price/Earnings ratio, GMAB is valued cheaper than 96.26% of the companies in the same industry.
GMAB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.03.
The Price/Forward Earnings ratio is 10.39, which indicates a very decent valuation of GMAB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.26% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.94. GMAB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.83 | ||
| Fwd PE | 10.39 |
4.2 Price Multiples
98.04% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
GMAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMAB is cheaper than 97.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.35 | ||
| EV/EBITDA | 7.17 |
4.3 Compensation for Growth
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.44
EPS Next 2Y2.37%
EPS Next 3Y8.76%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.52
+0.19 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners40.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.77B
Analysts76
Price Target117.18 (471.05%)
Short Float %0.4%
Short Ratio1.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)58.93%
Min EPS beat(2)-11.29%
Max EPS beat(2)129.15%
EPS beat(4)3
Avg EPS beat(4)47.14%
Min EPS beat(4)-11.29%
Max EPS beat(4)129.15%
EPS beat(8)5
Avg EPS beat(8)18.82%
EPS beat(12)8
Avg EPS beat(12)26.25%
EPS beat(16)11
Avg EPS beat(16)44.04%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-4.27%
Max Revenue beat(2)-1.54%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-4.27%
Max Revenue beat(4)6.12%
Revenue beat(8)6
Avg Revenue beat(8)1.47%
Revenue beat(12)10
Avg Revenue beat(12)3.15%
Revenue beat(16)14
Avg Revenue beat(16)4.46%
PT rev (1m)0%
PT rev (3m)-23.03%
EPS NQ rev (1m)-8.85%
EPS NQ rev (3m)84.8%
EPS NY rev (1m)0.56%
EPS NY rev (3m)9.56%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)6.13%
Revenue NY rev (1m)-1.77%
Revenue NY rev (3m)-0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.83 | ||
| Fwd PE | 10.39 | ||
| P/S | 3.94 | ||
| P/FCF | 11.35 | ||
| P/OCF | 10.91 | ||
| P/B | 2.31 | ||
| P/tB | 3.88 | ||
| EV/EBITDA | 7.17 |
EPS(TTM)1.6
EY7.8%
EPS(NY)1.98
Fwd EY9.63%
FCF(TTM)1.81
FCFY8.81%
OCF(TTM)1.88
OCFY9.17%
SpS5.21
BVpS8.89
TBVpS5.28
PEG (NY)N/A
PEG (5Y)0.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.12% | ||
| ROE | 21.38% | ||
| ROCE | 17.1% | ||
| ROIC | 13.92% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 124.64% | ||
| OM | 32.18% | ||
| PM (TTM) | 36.44% | ||
| GM | 95.42% | ||
| FCFM | 34.69% |
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)69.46%
ROICexc(5y)81.57%
ROICexgc(3y)103.42%
ROICexgc(5y)105.51%
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3Y22.47%
ROICexcg growth 5Y10.4%
ROICexc growth 3Y-22.82%
ROICexc growth 5Y-14.86%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.13 | ||
| Cap/Depr | 73.61% | ||
| Cap/Sales | 1.41% | ||
| Interest Coverage | 197.91 | ||
| Cash Conversion | 105.87% | ||
| Profit Quality | 95.19% | ||
| Current Ratio | 5.25 | ||
| Quick Ratio | 5.24 | ||
| Altman-Z | 7.81 |
F-Score5
WACC7.05%
ROIC/WACC1.97
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)24.67%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%-89.84%
EPS Next Y-12.51%
EPS Next 2Y2.37%
EPS Next 3Y8.76%
EPS Next 5Y7.42%
Revenue 1Y (TTM)30.67%
Revenue growth 3Y36.75%
Revenue growth 5Y32.03%
Sales Q2Q%14.19%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.53%
EBIT growth 1Y30.18%
EBIT growth 3Y33.83%
EBIT growth 5Y21.83%
EBIT Next Year35.31%
EBIT Next 3Y25.5%
EBIT Next 5Y13.95%
FCF growth 1Y6.61%
FCF growth 3Y55.76%
FCF growth 5Y43.79%
OCF growth 1Y5.3%
OCF growth 3Y51.65%
OCF growth 5Y42.43%